Cited by

• Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.

  Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Yarom N, et al. Osteoporos Int. 2007 Oct;18(10):1363-70. doi: 10.1007/s00198-007-0384-2. Epub 2007 Jun 28. Osteoporos Int. 2007. PMID: 17598065
• Intravenous bisphosphonates for postmenopausal osteoporosis.

  Mottaghi P. Mottaghi P. J Res Med Sci. 2010 May;15(3):175-84. J Res Med Sci. 2010. PMID: 21526078 Free PMC article.
• Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment.

  Simon MJ, Niehoff P, Kimmig B, Wiltfang J, Açil Y. Simon MJ, et al. Clin Oral Investig. 2010 Feb;14(1):51-8. doi: 10.1007/s00784-009-0312-2. Epub 2009 Jul 14. Clin Oral Investig. 2010. PMID: 19597852
• Differences between the bisphosphonates for the prevention and treatment of osteoporosis.

  Grey A, Reid IR. Grey A, et al. Ther Clin Risk Manag. 2006 Mar;2(1):77-86. Ther Clin Risk Manag. 2006. PMID: 18360583 Free PMC article.
• Establishment of an Animal Model of Bisphosphonate-Related Osteonecrosis of the Jaws in Spontaneously Diabetic Torii Rats.

  Takaoka K, Yamamura M, Nishioka T, Abe T, Tamaoka J, Segawa E, Shinohara M, Ueda H, Kishimoto H, Urade M. Takaoka K, et al. PLoS One. 2015 Dec 14;10(12):e0144355. doi: 10.1371/journal.pone.0144355. eCollection 2015. PLoS One. 2015. PMID: 26659123 Free PMC article.